Concepedia

Publication | Open Access

A Phase 1 Study of SLC-0111, a Novel Inhibitor of Carbonic Anhydrase IX, in Patients With Advanced Solid Tumors

DOIFull Paper Access

235

Citations

11

References

2020

Year

Paul C. McDonald, Stephen Chia, Philippe L. Bédard, Quincy Chu, Michael P. A. Lyle, Liren Tang, Madhu Singh, Zaihui Zhang, Claudiu T. Supuran, Daniel J. Renouf,
American Journal of Clinical Oncology

Abstract

SLC-0111 was safe in patients with previously treated, advanced solid tumors. The safety and pharmacokinetic data support 1000 mg/d as the recommended phase 2 dose for SLC-0111.

References

YearCitations

Page 1